AnaptysBio climbs on plans to split into two public companies

Shares of drug developer AnaptysBio ANAB.O rise 13.7% to over six-year high of $60.06

Co said late on Tuesday it is splitting into two public companies by Q2 of 2026, potentially as early as late April, one to collect drug royalties and one to develop new medicines

The new drug development company, First Tracks Biotherapeutics, trading under the ticker TRAX, will focus on treatments for autoimmune and inflammatory diseases

AnaptysBio's current CEO, Daniel Faga, is expected to lead both companies initially

ANAB also reported Q4 collab sales of $108.25 mln, compared to analysts est of $92.05 mln - LSEG

AnaptysBio ended 2025 with $311.6 million in cash

ANAB rose more than three-fold in 2025